N
Nanocarriers ......................................... 43, 45, 47, 52–54,
58, 125, 148
Nanoparticle
magnetic .............................................................. 69–80
Nanovesicles ............................................ 57–67, 147–167
Noncovalent .................................................115–117, 119
Non-homologous end joining (NHEJ).............. 183, 214
Non-viral.................................................... 4, 43, 125, 184
Nucleofection .................................... 194, 203, 204, 209,
222, 223, 227
O
Off-target analysis ................................................ 199, 206
P
Pectin ........................................................... 175, 176, 180
Peptide nucleic acids (PNAs) .............................. 124–139
Peptides ...................................16, 86, 97–120, 124, 125,
135–138, 148, 233, 234, 236–239
Pharmacokinetics ............................................... 58–62, 66
Phospholipid ................................................................... 59
Photodegradation ........................................................... 58
Plasmids .................................. 5, 7, 8, 13, 23, 44, 52, 71,
74, 87, 89, 90, 93, 94, 114–117, 119, 184, 194,
196–199, 201, 203, 204, 209, 215, 216, 218,
221–224, 227, 228
Polymers ................................................... 43, 44, 52, 125,
171–182
Polymyxin B ...................................................9, 16, 19, 22
Pools ............................................................ 162, 190, 194
Propidium iodide (PI) ......................................32, 37, 39,
60, 63, 67, 214
Protein
data analysis .................................................... 237, 238
extraction .......................................149, 233, 236, 238
identification.................................... 98, 109, 233–239
profiling .......................................................... 233–240
transduction.................................................. 85–95, 98
Proteomics............................................................ 233–239
Pseudo-peptide.............................................................. 124
R
Rat....................................................................... 87, 89, 99
Receptors ................................................. 98, 99, 103, 108
Reporter..................................................5, 16, 17, 23, 94,
117, 118, 120, 213–228
Rhodamine .....................................................65, 185, 188
Ribonucleoprotein (RNP) ............................................ 184
RNA-induced silencing complex (RISC) .................... 124
S
Sago ............................................................................... 175
Scaffolds........................................................184–190, 197
Seamless ......................................................................... 194
Shotgun ................................................................ 109, 234
Single guide RNA (sgRNA) ............................... 183–185,
187–190, 194, 196, 197, 199, 201–204, 209,
214–216, 218, 221
Single-stranded DNA oligonucleotide
(ssODN) .........................194, 197, 199, 204, 208
SnRNA.................................................................. 128, 133
T
Targeting ..........................................4, 97–112, 124, 126,
127, 134, 139, 147–150, 153, 156, 157, 185,
194, 197, 199, 201, 204, 209
Thalassemia..........................................139, 193, 194, 196
Transduction ........................................... 86, 97–111, 114
Transfection................................... 13, 14, 16, 22, 29, 72,
75–79, 114, 117, 120, 125, 126, 132, 184, 185,
204, 209, 215–218, 223–224, 227, 228
Trypan blue ....................................... 20, 21, 33, 35, 160,
164, 218, 220, 225
V
Vectors ................................................ 4, 9, 12–25, 29–33,
37, 38, 94, 98, 112, 123–139, 184, 194
Vitality................................................................... 126, 133
Z
Zeta potentials.................49, 54, 66, 153, 160, 162, 166
BIO-CARRIER VECTORS: METHODS AND PROTOCOLS
Index 243
Nanocarriers ......................................... 43, 45, 47, 52–54,
58, 125, 148
Nanoparticle
magnetic .............................................................. 69–80
Nanovesicles ............................................ 57–67, 147–167
Noncovalent .................................................115–117, 119
Non-homologous end joining (NHEJ).............. 183, 214
Non-viral.................................................... 4, 43, 125, 184
Nucleofection .................................... 194, 203, 204, 209,
222, 223, 227
O
Off-target analysis ................................................ 199, 206
P
Pectin ........................................................... 175, 176, 180
Peptide nucleic acids (PNAs) .............................. 124–139
Peptides ...................................16, 86, 97–120, 124, 125,
135–138, 148, 233, 234, 236–239
Pharmacokinetics ............................................... 58–62, 66
Phospholipid ................................................................... 59
Photodegradation ........................................................... 58
Plasmids .................................. 5, 7, 8, 13, 23, 44, 52, 71,
74, 87, 89, 90, 93, 94, 114–117, 119, 184, 194,
196–199, 201, 203, 204, 209, 215, 216, 218,
221–224, 227, 228
Polymers ................................................... 43, 44, 52, 125,
171–182
Polymyxin B ...................................................9, 16, 19, 22
Pools ............................................................ 162, 190, 194
Propidium iodide (PI) ......................................32, 37, 39,
60, 63, 67, 214
Protein
data analysis .................................................... 237, 238
extraction .......................................149, 233, 236, 238
identification.................................... 98, 109, 233–239
profiling .......................................................... 233–240
transduction.................................................. 85–95, 98
Proteomics............................................................ 233–239
Pseudo-peptide.............................................................. 124
R
Rat....................................................................... 87, 89, 99
Receptors ................................................. 98, 99, 103, 108
Reporter..................................................5, 16, 17, 23, 94,
117, 118, 120, 213–228
Rhodamine .....................................................65, 185, 188
Ribonucleoprotein (RNP) ............................................ 184
RNA-induced silencing complex (RISC) .................... 124
S
Sago ............................................................................... 175
Scaffolds........................................................184–190, 197
Seamless ......................................................................... 194
Shotgun ................................................................ 109, 234
Single guide RNA (sgRNA) ............................... 183–185,
187–190, 194, 196, 197, 199, 201–204, 209,
214–216, 218, 221
Single-stranded DNA oligonucleotide
(ssODN) .........................194, 197, 199, 204, 208
SnRNA.................................................................. 128, 133
T
Targeting ..........................................4, 97–112, 124, 126,
127, 134, 139, 147–150, 153, 156, 157, 185,
194, 197, 199, 201, 204, 209
Thalassemia..........................................139, 193, 194, 196
Transduction ........................................... 86, 97–111, 114
Transfection................................... 13, 14, 16, 22, 29, 72,
75–79, 114, 117, 120, 125, 126, 132, 184, 185,
204, 209, 215–218, 223–224, 227, 228
Trypan blue ....................................... 20, 21, 33, 35, 160,
164, 218, 220, 225
V
Vectors ................................................ 4, 9, 12–25, 29–33,
37, 38, 94, 98, 112, 123–139, 184, 194
Vitality................................................................... 126, 133
Z
Zeta potentials.................49, 54, 66, 153, 160, 162, 166
BIO-CARRIER VECTORS: METHODS AND PROTOCOLS
Index 243
Précédent